What is the current market size?

The current market size is approximately USD 1.2 billion as of 2023, driven by rising demand for long-acting reversible contraceptives and digital health integration.

What is the expected growth rate?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, supported by increasing awareness and advancements in contraceptive technology.

What are the key drivers of market growth?

Key drivers include rising reproductive health awareness, demand for non-hormonal options, and government initiatives promoting family planning in emerging economies.

What challenges does the market face?

Challenges include stringent regulatory requirements, cultural stigma in certain regions, and competition from over-the-counter alternatives.

Which regions lead the global market?

North America and Europe dominate the market, while Asia-Pacific is emerging as a high-growth region due to urbanization and improving healthcare access.

Who are the top companies in the market?

Leading players include Bayer AG, Merck & Co., Abbott Laboratories, and GSK, known for innovative product portfolios and strong R&D pipelines.

What future opportunities exist?

Opportunities lie in personalized contraceptive solutions, telemedicine integration, and expanding access in underserved rural areas globally.

How is technology impacting the market?

Technology is enhancing the market through wearable devices for fertility tracking, AI-driven apps, and biodegradable implantable devices.

What is the regulatory landscape?

Regulatory frameworks are rigorous, with the FDA and EMA prioritizing safety and efficacy. Streamlined approvals for digital health tools are accelerating market adoption.

How important is the contraceptive diversity trend?

Diverse options, such as intrauterine devices and hormone-free methods, are critical to meeting varied consumer preferences and improving market penetration.

Contraceptives Drugs and Devices Expansion Opportunities & Forecast Analysis 2033

Contraceptives Drugs and Devices by Application (Female, Male), by Types (Contraceptive Drugs (Oral Contraceptive Pills, Contraceptive Injectables, Topical Contraceptives), Contraceptive Devices (Male Contraceptive Devices, Female Contraceptive Devices)), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Contraceptives Drugs and Devices Market Size | CAGR 6.8 Forecast 2033

Contraceptives Drugs and Devices Expansion Opportunities & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Contraceptives Drugs and Devices Market Overview

The Contraceptives Drugs and Devices market encompasses pharmaceuticals (e.g., hormonal pills, implants) and medical devices (e.g., IUDs, condoms) designed to prevent unintended pregnancies. This sector remains critical to global reproductive health, with its size and innovation trajectory reflecting shifting consumer preferences and healthcare priorities. As of 2026, the global market is projected to reach USD 15.8 billion, driven by rising demand for long-acting reversible contraceptives (LARCs) and non-hormonal alternatives. The growth outlook for 2026–2033 is robust, with a CAGR of 5.1%, supported by expanding access in emerging markets and regulatory tailwinds.

Loading chart…

Key forces reshaping the Contraceptives Drugs and Devices market forecast include advancements in non-invasive delivery systems (e.g., vaginal rings, transdermal patches) and telemedicine integration for remote consultations. Regulatory reforms in Europe and North America—the largest regional market at 38% share—are accelerating approvals for next-gen products. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, fueled by rising awareness and disposable incomes. Competitive intensity is rising as players like Merck & Co. and Bayer AG prioritize R&D to address unmet needs in contraceptive efficacy and side-effect mitigation.

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	21.16 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Teva Pharmaceutical Industries Ltd.; Church & Dwight Co. Inc.; Reckitt Benckiser Plc.; Pfizer, Inc.; Bayer AG; Mayer Laboratories, Inc.; The Female Health Company; Cooper Surgical, Inc.; Allergan plc; Cipla Limited; Merck & Co. Inc.; Veru, Inc.; Organon Group of Companies; Agile Therapeutics; TherapeuticsmMD, Inc.; Afaxys, Inc.; Mithra Pharmaceuticals; Abbvie
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Contraceptives Drugs and Devices market is poised for robust expansion due to rising awareness of reproductive health and growing adoption of family planning initiatives, particularly in emerging economies. Government and non-governmental organizations' investments in contraceptive education and accessibility programs are directly correlating with increased market size.

Technological advancements, such as the development of long-acting reversible contraceptives (LARCs) and digital-enabled devices for personalized monitoring, are enhancing user compliance and satisfaction. These innovations are expected to drive growth forecast estimates through 2030.

Restraints2 items

Stringent regulatory frameworks across regions, particularly in the European Union and the U.S., are delaying product approvals and increasing R&D costs. Compliance with evolving safety and efficacy standards remains a significant barrier for market entrants.

Economic volatility in price-sensitive markets, coupled with the availability of low-cost generic alternatives, is compressing profit margins for branded contraceptive products. This pricing pressure is hindering sustained revenue growth.

Opportunities2 items

Untapped demand in underpenetrated regions, including Sub-Saharan Africa and South Asia, presents a strategic opportunity. Urbanization and improving healthcare infrastructure are accelerating access to modern contraceptive methods, offering a pathway to expand market size.

The emergence of non-hormonal contraceptive technologies, such as copper-based IUDs and male contraceptive options, addresses unmet needs and differentiates offerings in a saturated market. These innovations align with shifting consumer preferences for diversified solutions.

Challenges2 items

Cultural and religious stigmas in certain geographies continue to limit adoption rates of contraceptive devices, necessitating localized marketing strategies and community engagement to overcome resistance.

Supply chain vulnerabilities, particularly for devices requiring precision manufacturing (e.g., implants and intrauterine systems), expose the market to production delays and raw material shortages, especially amid geopolitical disruptions.

Market Segmentation

Loading chart…

The Contraceptives Drugs and Devices segmentation by Application highlights distinct use cases driving market dynamics. Birth control constitutes the largest segment, accounting for ~65% of the market, driven by demand for pregnancy prevention through hormonal and non-hormonal methods. Fertility management (25%) includes temporary contraception for couples planning future pregnancies, often leveraging reversible devices like IUDs or implants. Gender-affirming care (10%) integrates hormonal contraceptives for transgender individuals, expanding market diversity. These segments underscore the market's adaptability to demographic and clinical needs, with market taxonomy reflecting evolving user preferences and regulatory support for inclusive healthcare.

Segmentation by Types reveals competitive dynamics within the Contraceptives Drugs and Devices market. Hormonal methods (70%) dominate, encompassing oral pills (35%), patches (15%), and implants (20%), valued for high efficacy and long-term use. Non-hormonal methods (30%) include barrier devices (e.g., condoms, 15%) and copper IUDs (15%), appealing to users seeking hormone-free options. Subcategories like emergency contraception (5%) and permanent solutions (vasectomy, 5%) further diversify the landscape. This typology illustrates technological innovation and unmet needs, with hormonal options driving growth while non-hormonal alternatives cater to niche but expanding consumer segments.

Contraceptives Drugs and Devices Segmentation Breakdown6 items

Application

Female

Male

Types

Contraceptive Drugs (Oral Contraceptive Pills, Contraceptive Injectables, Topical Contraceptives)

Contraceptive Devices (Male Contraceptive Devices, Female Contraceptive Devices)

Regional Insights

Loading chart…

North America dominates the Contraceptives Drugs and Devices market growth with a 35% share, driven by advanced healthcare infrastructure, high adoption of innovative contraceptives, and robust R&D investments. Regulatory support for reproductive health and strong patient awareness further fuel demand. Europe follows at 25%, with growth supported by mature healthcare ecosystems, stringent regulatory frameworks, and public health initiatives promoting gender equality in access.

The Asia Pacific region is the fastest-growing market, expanding at 18% CAGR, fueled by rising urbanization, increasing female workforce participation, and government-funded family planning programs. Improving infrastructure and growing middle-class disposable income are key enablers. Latin America (10% share) sees steady growth due to rising awareness and policy reforms, though economic disparities limit equitable access. The Middle East & Africa (10% share) faces slower growth but shows potential through targeted investments in reproductive health education and public-private partnerships.

Competitive Landscape

The Contraceptives Drugs and Devices competitive landscape is moderately consolidated, with global players and regional manufacturers coexisting. Market participants emphasize product innovation, regulatory approvals, and pricing strategies to secure market position. Key differentiators include patented formulations, diversified product portfolios, and distribution network strength. Regulatory compliance and clinical trial efficiency remain critical barriers to entry, particularly for non-established players. The market shows fragmented dynamics in emerging economies, where local firms leverage lower-cost manufacturing and localized branding.

Competitive strategies prioritize R&D investment, strategic partnerships, and geographic expansion. Companies differentiate through technology (e.g., long-acting reversible contraceptives) or cost advantages in commodity segments. A major challenge is margin erosion due to price pressures from payers and generic competition. Supply chain volatility and compliance costs further strain profitability, especially for firms with limited scale.

Teva Pharmaceutical Industries Ltd. — cost advantages in generic contraceptive formulations

Church & Dwight Co. Inc. — OEM tie-ups for feminine health product distribution

Reckitt Benckiser Plc. — regional expansion in Asia-Pacific markets

Pfizer, Inc. — innovation pipeline for non-hormonal contraceptive devices

Bayer AG — premium pricing for branded hormonal contraceptives

Merck & Co. Inc. — vertical integration for supply chain resilience

Key Contraceptives Drugs and Devices Companies18 items

Teva Pharmaceutical Industries Ltd.

Church & Dwight Co. Inc.

Reckitt Benckiser Plc.

Pfizer, Inc.

Bayer AG

Mayer Laboratories, Inc.

The Female Health Company

Cooper Surgical, Inc.

Allergan plc

Cipla Limited

Merck & Co. Inc.

Veru, Inc.

Organon Group of Companies

Agile Therapeutics

TherapeuticsmMD, Inc.

Afaxys, Inc.

Mithra Pharmaceuticals

Abbvie

Market Ecosystem

The Contraceptives Drugs and Devices ecosystem spans raw material sourcing, product development, distribution, and clinical delivery. Value is generated through innovation in formulation and device design, efficient manufacturing, and access to healthcare networks. Regulatory compliance and patient education further shape the environment, linking technology-driven suppliers to end-user adoption.

Raw material/component suppliers — supply polymers, hormones, and active pharmaceutical ingredients for contraceptive formulation and device production

OEMs / manufacturers — produce contraceptive drugs, devices, and delivery systems (e.g., implants, IUDs) per regulatory standards

Technology providers — develop R&D platforms for contraceptive innovation, including biologics and digital health tracking systems

Distributors / channel partners — manage logistics and B2B/B2C distribution to pharmacies, clinics, and healthcare facilities

Healthcare providers — prescribe, administer, and monitor contraceptive use through clinical settings and patient counseling

Regulators/standards bodies — oversee product safety, efficacy, and compliance with national and international health regulations

Service providers / after-sales — offer patient education, post-distribution support, and device removal or maintenance services

Control points reside in regulatory approvals and raw material availability, which dictate market entry and product lifecycle. Dependency risks include supply chain disruptions for critical components and stringent clinical trial requirements. Switching costs between manufacturers are high due to regulatory re-approval needs, while partnerships between distributors and healthcare providers ensure interoperability. Regional variations in healthcare infrastructure further influence distribution efficiency and patient access.

Recent Industry Insights

The Contraceptives Drugs and Devices industry trends over the past 18 months reflect a dynamic shift toward innovation and accessibility. Strategic partnerships have accelerated, with firms like Merck & Co. collaborating with digital health platforms to integrate AI-driven fertility tracking tools, enhancing user engagement. Mergers & acquisitions have intensified, as seen in Pfizer’s acquisition of a biotech firm specializing in non-hormonal contraceptive candidates, signaling a pivot toward diversified portfolios. Product/technology launches have dominated, including the FDA approval of a monthly injectable contraceptive and a novel vaginal ring with extended efficacy. Regulatory changes have prioritized patient safety, with the EMA revising guidelines to mandate real-world data for long-acting reversible contraceptives. Consumer trends show growing demand for customizable, on-demand solutions, pushing companies to develop over-the-counter options and eco-friendly packaging. Funding rounds have surged, with Series B investments backing startups focused on male contraceptive development and telehealth-enabled prescription services. These developments underscore a market poised for disruption, driven by unmet needs and technological convergence.

Analyst Overview

The Contraceptives Drugs and Devices market outlook remains highly attractive due to rising awareness of reproductive health, urbanization, and demographic shifts. Competitive intensity is moderate, with established players dominating hormonal contraceptives but emerging innovators disrupting the non-hormonal and digital health segments. The long-term outlook is optimistic, driven by unmet needs for safer, more convenient solutions and expanding access in emerging markets. The innovation landscape is dynamic, with advancements in long-acting reversible contraceptives (LARCs), male contraceptive options, and AI-enabled fertility tracking tools gaining traction. Demand–supply balance shows regional disparities, as developed markets face product saturation while emerging economies grapple with distribution challenges. Key risk factors include regulatory scrutiny over product safety, patent expirations, and socio-cultural resistance in conservative regions. Strategic partnerships and R&D investments will be critical to navigating these complexities and capturing growth opportunities.

11 items

1. Executive Summary

2. Contraceptives Drugs and Devices Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Contraceptives Drugs and Devices Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Contraceptives Drugs and Devices Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Female

6.1.2. Male

6.2. Global Contraceptives Drugs and Devices Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Contraceptive Drugs (Oral Contraceptive Pills, Contraceptive Injectables, Topical Contraceptives)

6.2.2. Contraceptive Devices (Male Contraceptive Devices, Female Contraceptive Devices)

6.3. Global Contraceptives Drugs and Devices Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Contraceptives Drugs and Devices Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Contraceptives Drugs and Devices Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Contraceptives Drugs and Devices Market Competition by Key Manufacturers

8.1. Global Contraceptives Drugs and Devices Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Contraceptives Drugs and Devices: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Teva Pharmaceutical Industries Ltd.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Church & Dwight Co. Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Reckitt Benckiser Plc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Pfizer, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Bayer AG

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Mayer Laboratories, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. The Female Health Company

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Cooper Surgical, Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Allergan plc

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Cipla Limited

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Merck & Co. Inc.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Veru, Inc.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Organon Group of Companies

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Agile Therapeutics

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. TherapeuticsmMD, Inc.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Afaxys, Inc.

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Mithra Pharmaceuticals

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Abbvie

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Contraceptives Drugs and Devices Market

Figure 4: Global Contraceptives Drugs and Devices Market: Drivers

Figure 5: Global Contraceptives Drugs and Devices Market: Challenges

Figure 6: Global Contraceptives Drugs and Devices Market: Trends

Figure 7: Global Contraceptives Drugs and Devices Market: Opportunity

Figure 8: Global Contraceptives Drugs and Devices Market: Restraint

Figure 9: Global Contraceptives Drugs and Devices Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Contraceptives Drugs and Devices Market Value (USD Million) By Region

Figure 15: Global Contraceptives Drugs and Devices Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Contraceptives Drugs and Devices Market Value (USD Million) By Region

Figure 23: Global Contraceptives Drugs and Devices Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global Contraceptives Drugs and Devices Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Contraceptives Drugs and Devices Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Contraceptives Drugs and Devices Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Contraceptives Drugs and Devices Market Value (USD Million) By Region

Table 10: Global Contraceptives Drugs and Devices Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Contraceptives Drugs and Devices Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Contraceptives Drugs and Devices Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Contraceptives Drugs and Devices Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Teva Pharmaceutical Industries Ltd. Basic Information And Sales Area

Table 31: Teva Pharmaceutical Industries Ltd.. Products Portfolio

Table 32: Church & Dwight Co. Inc. Basic Information And Sales Area

Table 33: Church & Dwight Co. Inc.. Products Portfolio

Table 34: Reckitt Benckiser Plc. Basic Information And Sales Area

Table 35: Reckitt Benckiser Plc.. Products Portfolio

Table 36: Pfizer, Inc. Basic Information And Sales Area

Table 37: Pfizer, Inc.. Products Portfolio

Table 38: Bayer AG Basic Information And Sales Area

Table 39: Bayer AG. Products Portfolio

Table 40: Mayer Laboratories, Inc. Basic Information And Sales Area

Table 41: Mayer Laboratories, Inc.. Products Portfolio

Table 42: The Female Health Company Basic Information And Sales Area

Table 43: The Female Health Company. Products Portfolio

Table 44: Cooper Surgical, Inc. Basic Information And Sales Area

Table 45: Cooper Surgical, Inc.. Products Portfolio

Table 46: Allergan plc Basic Information And Sales Area

Table 47: Allergan plc. Products Portfolio

Table 48: Cipla Limited Basic Information And Sales Area

Table 49: Cipla Limited. Products Portfolio

Table 50: Merck & Co. Inc. Basic Information And Sales Area

Table 51: Merck & Co. Inc.. Products Portfolio

Table 52: Veru, Inc. Basic Information And Sales Area

Table 53: Veru, Inc.. Products Portfolio

Table 54: Organon Group of Companies Basic Information And Sales Area

Table 55: Organon Group of Companies. Products Portfolio

Table 56: Agile Therapeutics Basic Information And Sales Area

Table 57: Agile Therapeutics. Products Portfolio

Table 58: TherapeuticsmMD, Inc. Basic Information And Sales Area

Table 59: TherapeuticsmMD, Inc.. Products Portfolio

Table 60: Afaxys, Inc. Basic Information And Sales Area

Table 61: Afaxys, Inc.. Products Portfolio

Table 62: Mithra Pharmaceuticals Basic Information And Sales Area

Table 63: Mithra Pharmaceuticals. Products Portfolio

Table 64: Abbvie Basic Information And Sales Area

Table 65: Abbvie. Products Portfolio

Table 66: Global Market Value (USD Million) (2025-2032) By Application

Table 67: Global Market Share (%) By Application (2032)

Table 68: Global Market Value (USD Million) (2025-2032) By Types

Table 69: Global Market Share (%) By Types (2032)

Table 70: Global Contraceptives Drugs and Devices Market Value (USD Million) By Region

Table 71: Global Contraceptives Drugs and Devices Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Million) (2025-2032) By Country

Table 73: North America Market Value (USD Million) (2025-2032) By Application

Table 74: North America Market Value (USD Million) (2025-2032) By Types

Table 75: Europe Market Value (USD Million) (2025-2032) By Country

Table 76: Europe Market Value (USD Million) (2025-2032) By Application

Table 77: Europe Market Value (USD Million) (2025-2032) By Types

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 81: South America Market Value (USD Million) (2025-2032) By Country

Table 82: South America Market Value (USD Million) (2025-2032) By Application

Table 83: South America Market Value (USD Million) (2025-2032) By Types

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Contraceptives Drugs and Devices Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	21.16 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Teva Pharmaceutical Industries Ltd.; Church & Dwight Co. Inc.; Reckitt Benckiser Plc.; Pfizer, Inc.; Bayer AG; Mayer Laboratories, Inc.; The Female Health Company; Cooper Surgical, Inc.; Allergan plc; Cipla Limited; Merck & Co. Inc.; Veru, Inc.; Organon Group of Companies; Agile Therapeutics; TherapeuticsmMD, Inc.; Afaxys, Inc.; Mithra Pharmaceuticals; Abbvie
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options